Efficacy of JAK-JANUS Kinase Inhibitors as Mono Therapy and in Combination with Methotrexate in Active Rheumatoid Arthritis
DOI:
https://doi.org/10.51253/pafmj.v74iSUPPL-2.11979Keywords:
Active rheumatoid arthritis, Combination treatment, Janus kinase inhibitors, Methotrexate, Monotherapy.Abstract
Objective: To compare the efficacyof Janus kinase inhibitors as mono therapy and in combination with methotrexate in patients with active rheumatoid arthritis.
Study Design: Quasi-experimental study.
Place and Duration of Study: Department of Medicine, Combined Military Hospital, Hospital Multan, Pakistan, from Nov 2022 to Oct 2023.
Methodology: A total of 1194 patients aging 18 years or above with active rheumatoid arthritis and taking Tofacitinab (5 mg twice daily) were included in this study. In Group-A patients were continued with oral Tofacitinab (5 mg twice daily) while patients in Group-B were added oral methotrexate (15–25 mg per week). The study’s primary outcome was set as the number of patients achieving ACR50 at 6 months of the treatment. Secondary outcomes were the patients achieving ACR70, low disease activity (SDAI ≤11), remission (SDAI ≤3.3) and response of ≥0.22 in HAQ-D index at 6 months follow up.
Results: The Mean±SD of age in this study was 51.66±9.36 years. The female gender was 72.61% of total population while males were 27.39%. The results of the primary outcomes of the study show a statistically significant difference between Group-A and Group-B (39.20% Vs 44.72 respectively, p=0.05) proving the combination therapy to be more effective than monotherapy. Among secondary end points, significantly more patients achieved ACR 70 rate, SDAI ≤11 and SDAI ≤3.3 in Group-B compared to Group-A, however, no statistically significant difference was present regarding achieving ≥0.22 response at HAQ-D index.
Conclusion: The combination of a JAK inhibitor with methotrexate is more effective in the treatment of
Downloads
References
Sparks JA. Rheumatoid arthritis. Ann Internal Med 2019; 170(1): Itc1–itc16.
https://doi: 10.7326/AITC201901010
Hock ES, James MM, Wailoo A, Scott DL, Stevenson M, Rawdin A, et al. Treat-to-Target Strategies in Rheumatoid Arthritis: a Systematic Review and Cost-Effectiveness Analysis. SN Compr. Clin. Med 2021; 3: 838–854.
https://doi.org/10.1007/s42399-021-00727-4
Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA 2018; 320(13): 1360–1372. https://doi:10.1001/jama.2018.13103
Fragoulis GE, Brock J, Basu N, McInnes IB, Siebert S. The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions. J Allergy ClinImmunol 2021; 148(4): 941-952. https://doi: 10.1016/j.jaci.2021.08.010
Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2021; 73(7): 1108-1123.
https://doi: 10.1002/art.41752
Lau CS, Chia F, Dans L, Harrison A, Hsieh TY, Jain R, et al. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis 2019; 22: 357–375.
Food and Drug Administration. [Online] [cited 2023 Nov 12]. Available from: URL:
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208246.
Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatol (Oxford) 2019; 58(6): 953-962.
https://doi: 10.1093/rheumatology/key339
Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018; 391(10139): 2503-2512.
https://doi: 10.1016/S0140-6736(18)31115-2
Combe B, Kivitz A, Tanaka Y, van der Heijde D, Simon JA, Baraf HSB et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis 2021; 80(7): 848-858.
https://doi: 10.1136/annrheumdis-2020-219214
Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 2017; 76(1): 88-95. https://doi: 10.1136/annrheumdis-2016-210094.
Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with janus kinase inhibitors: a consensus statement. Ann rheumatic Dis 2021; 80(1): 71–87. https://doi: 10.1136/annrheumdis-2020-218398
Emery P, Pope JE, Kruger K, Lippe R, DeMasi R, Lula S et al. Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review. AdvTher 2018; 35(10): 1535-1563.
https://doi: 10.1007/s12325-018-0757-2
Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, et al. ORAL Strategy investigators. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet 2017; 390(10093): 457-468.
https://doi: 10.1016/S0140-6736(17)31618-5
Whittall Garcia LP, Gladman DD, Urowitz M, Touma Z, Su J, Johnson SR, et al. New EULAR/ACR 2019 SLE Classification Criteria: defining ominosity in SLE. Ann Rheum Dis. 2021; 80(6): 767-774. https://doi: 10.1136/annrheumdis-2020-218670
Lee EB, Fleischmann R, Hall S. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014; 370: 2377–2386.
Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol (Hoboken NJ) 2017; 69(3): 506–517. https://doi:10.1002/art.39953
Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann rheumatic Dis 2021; 80(6): 727–38.
doi: 10.1136/annrheumdis-2020-219213
Taylor PC, Laedermann C, Alten R, Feist E, Choy E, Haladyj E, et al. A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience. J Clin Med 2023; 12(13): 4527.
https://doi: 10.3390/jcm12134527. PMID: 37445562; PMCID: PMC10342289.
Liu L, Yan YD, Shi FH, Lin HW, Gu ZC, Li J et al. Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis. Front Immunol 2022; 13: 977265.
https://doi: 10.3389/fimmu.2022.977265
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Hamna Wajid, Fawad Rahman, Lt col Zahid Hussain Rana, Lt col Rizwan Azam, Dr Sidra Batool, Dr Zoha Hashmi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
